Vonoprazan Dual or Triple Therapy Versus Bismuth‐Quadruple Therapy as First‐Line Therapy for <i>Helicobacter pylori</i> Infection: A Three‐Arm, Randomized Clinical Trial
Authors
Ho Yu Ng (ORCID: https://orcid.org/0009-0008-7949-5398)
Jing Tong Tan (ORCID: https://orcid.org/0000-0002-3973-5376)
Zijie Deng
Ni Li (ORCID: https://orcid.org/0000-0001-5530-7745)
Tao Lyu (ORCID: https://orcid.org/0000-0001-5162-8103)
Wai K. Leung (ORCID: https://orcid.org/0000-0002-5993-1059)
Ka Shing Cheung (ORCID: https://orcid.org/0000-0002-4838-378X)
Vonoprazan Dual or Triple Therapy Versus Bismuth‐Quadruple Therapy as First‐Line Therapy for Helicobacter pylori Infection: A Three‐Arm, Randomized Clinical Trial
Vonoprazan Dual or Triple Therapy Versus Bismuth‐Quadruple Therapy as First‐Line Therapy for Helicobacter pylori Infection: A Three‐Arm, Randomized Clinical Trial
Ho Yu Ng, Jing Tong Tan, Zijie Deng, Ni Li, Tao Lyu, Wai K. Leung, Ka Shing Cheung, Jian Qin, Juan Wu, Shaowei Han, Wai‐Kay Seto
article en
17 citations
Abstract
No abstract available for this paper.
Publication Tag
HelicobacterVol. 29(5)
Institutions
Chinese University of Hong Kong (HK), University of Hong Kong - Shenzhen Hospital (CN), Yulin Orthopedics Hospital of Chinese and Western Medicine (CN), University of Hong Kong (HK)